A Multi-centric Study to Assess the Efficacy of Sigmart in Subjects With Recurrent Angina After Coronary Revascularization

NCT01185015 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Angina Pectoris

Interventions

DRUG: Sigmart (nicorandil)

Sponsor

Merck KGaA, Darmstadt, Germany